And there's not really anything that we've discovered that makes us aware of who would be at risk
If youre looking for weight loss in the range of what GLP-1 medications produce, this isnt the right comparison
TRIUMPH-CVOT is the cardiovascular outcomes trial, enrolling approximately 10,000 participants with established cardiovascular disease over a 3-4 year timeline, with MACE as the primary endpoint
Important Medical Reality It is also important not to romanticize GLP-1 medications
This approach reflects a broader trend in healthcare, where financialization drives profit maximization at the expense of equity and accessibility
They may be suitable for people who want a needle-free alternative to GLP-1 injections, subject to BMI, medical history, current medicines and prescriber approval